Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study

Table 5

Univariate analysis of variables associated with adverse maternal outcomes.

Characteristics	PIH
	Yes ()	No ()	value
Disease flares during pregnancy	22(75.9)	30(14.0)	<0.001
Active lupus nephritis	18(62.1)	27(12.6)	<0.001
Thrombocytopenia	9(31.0)	14(6.5)	<0.001
Leukopenia	3(10.3)	4(1.9)	0.04
Anti-dsDNA antibody positivity	12(41.4)	81(37.9)	0.7
Anti-Ro antibody positivity	14(48.3)	85(39.7)	0.4
Anti-La antibody positivity	2(6.9)	31(14.5)	0.4
LAC positivity	7(24.1)	12(5.6)	0.003
Anticardiolipin antibody positivity	15(51.7)	14(6.5)	<0.001
Anti-beta2 GP1 positivity	1(3.4)	20(9.3)	0.5
Hypoalbuminemia	11(37.9)	55(25.7)	0.2
Hypocomplementemia	14(48.3)	42(19.6)	0.001
Hydroxychloroquine	13(44.8)	113(52.8)	0.4